2025 United Kingdom Autologous Cell Therapy Market Revenue Opportunities Report
Description
The 2025 United Kingdom Autologous Cell Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK autologous cell therapy market are Autolus Therapeutics, Orchard Therapeutics, Purespring Therapeutics, and Rinri Therapeutics. Autolus, based in London, is a clinical-stage CAR-T cell therapy company focusing on personalized cancer treatment, having recently gained FDA approval for its lead CAR-T product, obe-cel, used against relapsed B-cell precursor acute lymphoblastic leukemia. Orchard Therapeutics, headquartered in London, specializes in hematopoietic stem cell gene therapies targeting rare genetic diseases, emphasizing curative potential through autologous approaches. Purespring Therapeutics, also London-based, concentrates on preclinical AAV gene therapies for chronic renal diseases, exploring regenerative solutions within the autologous cell therapy framework. Rinri Therapeutics, located in Sheffield, pioneers regenerative cell therapies for hearing loss, advancing near-clinical stage autologous treatments.
These companies exemplify the UK's leadership in autologous cell therapy by combining advanced research, regulatory progress, and strategic collaborations. Autolus, with strong industry partnerships such as with Moderna and Bristol Myers Squibb, is innovating modular T-cell programming for oncology. Orchard and Purespring harness gene therapy technologies to develop potentially curative treatments for rare and chronic diseases, representing vital segments in the UK market. Rinri's focus on regenerative therapies for sensory disorders expands the autologous cell therapy applications beyond oncology. Collectively, their integration in manufacturing expansions and clinical trial activities contributes significantly to the UK’s rapidly growing cell therapy market, which forecasts a CAGR over 25% through 2035.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK autologous cell therapy market are Autolus Therapeutics, Orchard Therapeutics, Purespring Therapeutics, and Rinri Therapeutics. Autolus, based in London, is a clinical-stage CAR-T cell therapy company focusing on personalized cancer treatment, having recently gained FDA approval for its lead CAR-T product, obe-cel, used against relapsed B-cell precursor acute lymphoblastic leukemia. Orchard Therapeutics, headquartered in London, specializes in hematopoietic stem cell gene therapies targeting rare genetic diseases, emphasizing curative potential through autologous approaches. Purespring Therapeutics, also London-based, concentrates on preclinical AAV gene therapies for chronic renal diseases, exploring regenerative solutions within the autologous cell therapy framework. Rinri Therapeutics, located in Sheffield, pioneers regenerative cell therapies for hearing loss, advancing near-clinical stage autologous treatments.
These companies exemplify the UK's leadership in autologous cell therapy by combining advanced research, regulatory progress, and strategic collaborations. Autolus, with strong industry partnerships such as with Moderna and Bristol Myers Squibb, is innovating modular T-cell programming for oncology. Orchard and Purespring harness gene therapy technologies to develop potentially curative treatments for rare and chronic diseases, representing vital segments in the UK market. Rinri's focus on regenerative therapies for sensory disorders expands the autologous cell therapy applications beyond oncology. Collectively, their integration in manufacturing expansions and clinical trial activities contributes significantly to the UK’s rapidly growing cell therapy market, which forecasts a CAGR over 25% through 2035.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
